Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401206 | 0.91 | CASP3 (0.55) | HDAC1HDAC2KMT2AIDO1CASP3 | |
| SCHEMBL31348914 | 0.91 | CASP3 (0.55) | HDAC1HDAC2KMT2AIDO1CASP3 | |
| SCHEMBL6588912 | 0.91 | CASP3 (0.55) | HDAC1HDAC2KMT2AIDO1CASP3 | |
| SCHEMBL31348963 | 0.91 | CASP3 (0.55) | HDAC1HDAC2KMT2AIDO1CASP3 | |
| SCHEMBL29401236 | 0.91 | CASP3 (0.55) | HDAC1HDAC2KMT2AIDO1CASP3 | |
| SCHEMBL28792081 | 0.89 | HDAC1 (0.54) | HDAC1HDAC2KMT2AIDO1MDM4 | |
| SCHEMBL15886222 | 0.89 | HDAC1 (0.51) | HDAC1HDAC2KMT2AIDO1CASP3 | |
| SCHEMBL25297393 | 0.89 | KMT2A (0.56) | HDAC1HDAC2KMT2AIDO1CASP3 | |
| SCHEMBL13411488 | 0.89 | KMT2A (0.56) | HDAC1HDAC2KMT2AIDO1CASP3 | |
| SCHEMBL17446645 | 0.88 | HDAC1 (0.57) | HDAC1HDAC2KMT2AIDO1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068692-A1 | ANTIFREEZE GLYCOPROTEIN ANALOGUES AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068692-A1 | ANTIFREEZE GLYCOPROTEIN ANALOGUES AND USES THEREOF | SRRM2, MSR1, CD59 | HDAC1 2107/4885HDAC2 1970/4885KMT2A 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.